581 results
Page 6 of 30
6-K
EX-99.1
lr54el
30 Sep 15
IMPORTANT NEW DATA FROM TEVA’S TEV-48125 PHASE 2b MIGRAINE PROGRAM PUBLISHED INLANCET NEUROLOGYIN BACK-TO-BACK ARTICLES
12:00am
6-K
EX-99.1
clixt9dqk r8jw
28 Sep 15
Teva Announces Approval of COPAXONE® in Japan for the Prevention of Relapse of Multiple Sclerosis
12:00am
6-K
EX-99.1
pw75xj3ols8
28 Sep 15
Teva Presents New Reslizumab Data at European Respiratory Society (ERS) International Congress 2015
12:00am
6-K
EX-99.1
aw4voitimatezxkr
8 Sep 15
Live Filing
12:00am
6-K
EX-99.1
967psp
27 Jul 15
Teva to Acquire Allergan Generics for $40.5 Billion
12:00am
6-K
EX-99.3
my7h c38btl3ksop7
27 Jul 15
Teva to Acquire Allergan Generics for $40.5 Billion
12:00am
425
oacduzvgwjvqi
21 Apr 15
Business combination disclosure
12:00am
6-K
EX-99.1
aq0kv fthblcq
21 Apr 15
Teva Proposes to Acquire Mylan for $82.00 Per Share In Cash and Stock
12:00am
425
wmd7kksh5fm8zustxys0
21 Apr 15
Business combination disclosure
12:00am
6-K
EX-99.1
abjt1fgo56e8nxysu3
23 Mar 15
Teva Announces New Head of Business Development, Strategy and Innovation
12:00am
6-K
EX-99.1
bfv8n 4fkys40eaivxj
23 Mar 15
Live Filing
12:00am
6-K
EX-99.1
qf5z1bza
2 Mar 15
Teva Announces Sale of Sellersville, PA Facility
12:00am
6-K
EX-99.1
ohp9mx yv3
27 Feb 15
Live Filing
12:00am
6-K
EX-99.1
9dzqle
25 Feb 15
Live Filing
12:00am
6-K
EX-99.1
ml5k 1ouyghbyeq
24 Feb 15
TEVA ANNOUNCES POSITIVE RESULTS FOR TEV-48125 IN PHASE IIb CHRONIC MIGRAINE STUDY MEETING PRIMARY AND SECONDARY ENDPOINTS
12:00am
6-K
EX-99.1
mfc6w9j2bqvxje
23 Feb 15
Live Filing
12:00am
6-K
EX-99.1
rn8u3t
20 Feb 15
Teva to Present New Respiratory Data at 2015 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
12:00am
6-K
EX-99.1
05fm zikuusil
5 Feb 15
Live Filing
12:00am